Country: Ireland
Bahasa: Inggeris
Sumber: HPRA (Health Products Regulatory Authority)
SODIUM CHLORIDE SODIUM LACTATE POTASSIUM CHLORIDE CALCIUM CHLORIDE DIHYDRATE
Baxter Healthcare Limited
SODIUM CHLORIDE SODIUM LACTATE POTASSIUM CHLORIDE CALCIUM CHLORIDE DIHYDRATE
1
Solution for Infusion
Product subject to prescription which may not be renewed (A)
Authorised
0000-00-00
SUMMARY OF PRODUCT CHARACTERISTICS 1 NAME OF THE MEDICINAL PRODUCT Compound Sodium Lactate Intravenous Infusion BP, (Hartmann’s Solution) Solution for Infusion 2 QUALITATIVE AND QUANTITATIVE COMPOSITION Each litre provides the following concentration of electrolytes: For a full list of excipients, see section 6.1. 3 PHARMACEUTICAL FORM Solution for infusion Sterile, non-pyrogenic, clear, colourless, aqueous solution for infusion. 4 CLINICAL PARTICULARS 4.1 THERAPEUTIC INDICATIONS For prophylactic and replacement therapy requiring the use of Sodium Chloride and lactate, with minimal amounts of calcium and potassium. 4.2 POSOLOGY AND METHOD OF ADMINISTRATION 4.2.1 DOSAGE The dosage is dependant upon the age, weight and clinical condition of the patient. 4.2.2 ADMINISTRATION Intravenous. 4.3 CONTRAINDICATIONS 4.3.1 Administration in congestive heart failure, or in conditions of severe impairment of renal function, or in oedema with sodium retention. 4.3.2 Lactate containing solutions are contraindicated in patients with liver disease. Sodium Chloride 6.0 g/l Sodium Lactate 3.22 g/l Potassium Chloride 400 mg/l Calcium Chloride Dihydrate 270 mg/l Na + 131 mmol/l K + 5 mmol/l Cl ¯ 111 mmol/l Lactate 29 mmol/l Ca + 2 mmol/l HEALTH PRODUCTS REGULATORY AUTHORITY ________________________________________________________________________________________________________________________ _Date Printed 05/08/2014_ _CRN 2150440_ _page number: 1_ 4.4 SPECIAL WARNINGS AND PRECAUTIONS FOR USE 4.4.1 Administration should be carried out under regular and careful surveillance; plasma electrolyte levels should be monitored during use. 4.4.2 This fluid should be administered with great care to patients with renal insufficiency. 4.5 INTERACTION WITH OTHER MEDICINAL PRODUCTS AND OTHER FORMS OF INTERACTION None known. 4.6 FERTILITY, PREGNANCY AND LACTATION The safet Baca dokumen lengkap